On October 17, 2017 Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) reported that new data investigating the use of eftilagimod alpha (IMP321), the Company’s lead product candidate, in combination with pembrolizumab in metastatic melanoma patients in Australia that have had either no response or a suboptimal response to pembrolizumab, will be presented in a poster presentation for the first time at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2017 Annual Meeting (Press release, Prima Biomed, OCT 17, 2017, View Source [SID1234520988]).

Pushing the accelerator and releasing the break: testing the soluble LAG-3 protein (IMP321), an antigen presenting cell activator, together with pembrolizumab in unresectable or metastatic melanoma. Poster Number P259
Authors: Victoria Atkinson, Andrew Haydon, Melissa Eastgate, Amitesh Roy, Adnan Khattak, Christian Mueller, Tina Dunkelmann, Chrystelle Brignone, Frederic Triebel
The SITC (Free SITC Whitepaper) 2017 Annual Meeting is being held on November 10-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

On October 17, 2017 Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “company”), an oncology-focused, clinical stage biotechnology company, reported the Japanese Patent Office has granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125, two of the company’s phospholipid drug conjugates (PDCs) (Press release, Cellectar Biosciences, OCT 17, 2017, View Source [SID1234520987]). Both compounds are composed of radio isotopes conjugated to the company’s proprietary PDC delivery platform. CLR 131 is the company’s lead compound and is currently in a Phase 1 trial for multiple myeloma and a Phase 2 trial for multiple blood cancers. CLR 125 was part of a National Cancer Institute (NCI)-sponsored study showing potential effect against triple-negative breast cancer.

The recently issued patent, JP 2014-147869 (Phospholipid Analogs as Diapeutic Agents) provides intellectual property protection for both diagnostic and therapeutic applications. Most significantly, the patent includes five claims for CLR 131 and CLR 125 in treating multiple solid tumor cancer types, including brain (glioma), colorectal, intestinal, ovarian, cervical, pancreatic, lung, adrenal, retinoblastoma and skin cancers, as well as squamous cell cancers (cancers of the lining of hollow organs, i.e., head and neck cancer, bladder cancer, etc.). Cellectar Biosciences holds the exclusive, worldwide rights to develop and commercialize both CLR 131 and CLR 125.

“The issuance of this Japanese patent enhances our growing intellectual property portfolio in this strategically important market and underscores the novelty of our delivery platform and the potential of these compounds. Certain cancers such as head and neck and gastric are more prevalent in Asia and represent high unmet medical need both within and outside the region,” said Jim Caruso, president and CEO of Cellectar. “The increased market protection provided by this patent combined with the ongoing NCI supported research in head and neck cancer and the early clinical benefits seen to date with CLR 131, affords us the opportunity to initiate a more global development program.”

About CLR 131
CLR 131 is an investigational compound under development for a range of hematologic malignancies. It is currently being evaluated as a single-dose treatment in a Phase 1 clinical trial in patients with relapsed or refractory (R/R) multiple myeloma (MM) as well as in a Phase 2 clinical trial for R/R MM and select R/R lymphomas as either a one- or two-dose treatment. CLR 131 represents a novel approach to treating hematological diseases and based upon preclinical and interim Phase 1 study data, may provide patients with therapeutic benefits including, overall survival, an improvement in progression-free survival, and overall quality of life. CLR 131 utilizes the company’s patented PDC tumor targeting delivery platform to deliver a cytotoxic radioisotope, iodine-131, directly to tumor cells. The FDA has granted Cellectar an orphan drug designation for CLR 131 in the treatment of multiple myeloma.

About CLR 125
CLR 125 utilizes the company’s patented PDC tumor targeting delivery platform to deliver a radiotherapeutic isotope, iodine-125, directly to tumor cells. This compound may be uniquely suited to treat select cancers, such as triple negative breast cancer, and micro-metastatic disease. Iodine-125 is a low energy gamma emitting isotope that when selectively delivered to tumor cells can result in improved outcomes.

About Phospholipid Drug Conjugates (PDCs)
Cellectar’s product candidates are built upon its patented cancer cell-targeting delivery and retention platform of optimized phospholipid ether-drug conjugates (PDCs). The company designed its phospholipid ether (PLE) carrier platform to be coupled with a variety of payloads to facilitate the discovery and development of improved targeted novel therapeutic compounds. The basis for selective tumor targeting of our PDC compounds lies in the differences between the plasma membranes of cancer cells compared to those of normal cells. Cancer cell membranes are highly enriched in lipid rafts, which are glycolipoprotein microdomains of the plasma membrane of cells that contain high concentrations of cholesterol and sphingolipids, and serve to organize cell surface and intracellular signaling molecules. PDCs have been tested in more than 80 different xenograft models of cancer.

On October 17, 2017 Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, reported that it has entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan plc, for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the Mixed Lineage Leukemia (“MLL”) protein (Press release, Syndax, OCT 17, 2017, View Source [SID1234520984]). These compounds have potential application in the treatment of a genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene (“MLL-r”). Syndax expects to initiate clinical studies in 2019.

“This agreement represents another strategic addition to our pipeline that we believe will enhance the long-term value of Syndax,” said Briggs W. Morrison, M.D., Chief Executive Officer of Syndax. “Syndax is well positioned to develop this unique product portfolio which holds the potential to significantly change the treatment paradigm for acute leukemic patients harboring MLL translocations, a disease that may meet the guidelines for orphan designation.”

“The Menin-MLL-r interaction is thought to play a central role in the pathology of acute leukemia patients with MLL translocations, a patient population routinely identified in clinical practice today,” said Michael L. Meyers, M.D., Ph.D., Chief Medical Officer of Syndax. “While intensive chemotherapy regimens are often employed in these patients, the 5-year survival rate remains significantly below 50% due to the lack of effective treatment options. We believe that this portfolio of compounds holds the potential to serve as an effective oral therapeutic option for pediatric and adult patients with MLL-r-driven leukemias.”

Under the terms of the license agreement, Syndax will make a one-time upfront payment to Allergan and will be responsible for development, manufacturing and global commercialization of the portfolio. Allergan will receive development and commercial stage milestones and tiered royalties on net sales of commercialized products.
About MLL Rearranged (MLL-r) Leukemias

Rearrangements of the MLL gene occur in 70-80% of infant acute leukemias and up to 10% of adult acute leukemias and are associated with a poor prognosis, with less than 40% of infants with MLL-r surviving past 5 years. The protein products of MLL gene rearrangements require interaction with a protein called Menin in order to drive leukemic cancer growth. Disruption of the Menin-MLL-r interaction has been shown to halt the growth of MLL-r leukemic cells. MLL-r leukemias are routinely diagnosed through currently available genetic screening techniques in leukemic cells, but there are currently no approved therapies indicated for MLL-r leukemias.

On October 17, 2017 PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, reported that its research partner, the University of Northern Colorado (UNC), has identified an organism whose genome contains the genetic code for production of an enzyme capable of activating a cannabinoid prodrug into its active cancer-killing form (Press release, PharmaCyte Biotech, OCT 17, 2017, View Source [SID1234520983]).

“We are pleased that UNC has taken us one step closer to developing cannabinoid-based therapies to combat cancer utilizing our proprietary Cell-in-a-Box live-cell encapsulation technology,” commented PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner. “PharmaCyte’s innovative Cannabis Program has established PharmaCyte as a serious player in the medical Cannabis sector, and we are exploring additional strategic relationships to advance product development and commercialization.”

PharmaCyte’s Cannabis Program has had two primary areas of focus. The first is confirming the anti-cancer activity of cannabinoids (constituents of the Cannabis plant), such as tetrahydrocannabinol (THC) and cannabidiol (CBD). UNC’s research has confirmed that a purified cannabinoid showed a potent dose-dependent decrease in cell viability for various cancers, suggesting that this cannabinoid exhibits significant anti-proliferative effects (stops the growth of cancer cells). This activity has been demonstrated in glioblastoma (brain), pancreatic, breast, lung, colon and melanoma cancer cell lines.

The second area of focus is in finding an enzyme capable of converting an inactive, side-effect-free, cannabinoid prodrug into its active cancer-killing form. The research team at UNC has screened numerous cell lines and numerous enzymes. As result of this extensive work, an organism has been identified that has been confirmed to produce an enzyme capable of catalyzing the desired cannabinoid-prodrug-activating reaction. Work is now underway to locate the enzyme’s gene.

Dr. Mark L. Rabe, PharmaCyte’s Director of Cannabis Program Development, commented, “Our work at UNC continues to bear fruit. The work with cancer cell lines not only confirmed cannabinoid anti-cancer activity, it generated important dosing data. The work to identify the needed activating enzyme has been intensive and time-consuming, and we are pleased to have identified a front-running candidate that has exhibited the desired activity.”

Once the location of the activating enzyme gene has been determined within the organism’s genome, a series of steps will occur to amplify and clone the gene and confirm its activity. The gene will then be used to bio-engineer a human cell line that will then become a cannabinoid-prodrug-activating enzyme “factory.” Importantly, the parental human cell line that will be utilized is the same cell line being utilized in PharmaCyte’s therapy for pancreatic cancer. Upon confirmation of the desired activity by the bio-engineered cell line, the final steps include live-cell encapsulation with the Cell-in-a-Box technology and validation.

Clinically, targeted cannabinoid-based chemotherapy would be accomplished by implanting the encapsulated bio-engineered cells near the site of a tumor, along with administration of a cannabinoid prodrug which would become activated at the site of the tumor by an enzyme produced by the encapsulated cells. The end goal is better efficacy than existing therapies with few, if any, side effects.

On October 17, 2017 Varian (NYSE: VAR) reported an 80-year-old male with head & neck cancer became the first patient in Europe to be treated on the Halcyon system at University Hospitals Leuven (UZ Leuven) in Belgium (Press release, InfiMed, OCT 17, 2017, View Source [SID1234520980]). Halcyon is an advanced cancer treatment system that is more comfortable for the patient while delivering ease-of-use for healthcare providers, accelerated installation timeframes, expedited commissioning, simplified training, and automated treatment.

Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), and is designed to expand the availability of high-quality cancer care globally and help save the lives of millions more cancer patients. It is well suited to handle the majority of cancer patients, offering advanced treatments for lung, esophagus, brain, head & neck, and many other forms of cancer.

“We selected the Halcyon system because of its potential to accelerate the treatment workflow and allow for a much closer connection between the patient and therapist,” said professor Karin Haustermans, MD, chair of the department, UZ Leuven. “Having now completed our first treatments I can say that Halcyon lived up to its promise of a more efficient workflow and better integration of imaging and treatment, which resulted in a much faster overall treatment time.”

“We are very proud to have partnered with UZ Leuven on making Halcyon treatments available to patients in Europe just two months after the hospital ordered this new system,” said Kolleen Kennedy, president of Varian’s Oncology Systems business. “The treatments beginning at UZ Leuven are another important step in continuing our efforts of advancing cost-effective cancer care worldwide.”

For more information on Halcyon, visit www.varian.com/halcyon